본문 바로가기
KERD
논문KCI 등재

Immunohistochemical and Molecular Markers Associated with Differentiated Thyroid Carcinoma

최준영|박귀원|이규언|정준우
대한갑상선학회 (Korean Thyroid Association)|2015.05|International Journal of Thyroidology|제8권 제1호|pp. 50-60

2

조회

0

다운로드

1

인용

0

참고문헌

키워드

ImmunohistochemistryMolecular markersDifferentiated thyroid carcinoma
주제분류의학일반

초록

In the last decade, conventional diagnosis of thyroid nodules largely depended on fine-needle aspiration (FNA) and ultrasound. However, FNA has a limited ability to distinguish between benign and malignant lesions, especially in cases with indeterminate cytology. Although the clinical course of differentiated thyroid carcinoma is believed to be favorable, delayed diagnosis can make its clinical management difficult. Many immunohistochemical (IHC) or molecular adjunctive markers have been tested to improve the diagnostic accuracy for thyroid nodules. The common IHC markers galectin-3, Hector Battifora mesothelial-1, and cytokeratin-19 are used alone or as part of panels for both FNA and analysis of surgical specimens. A novel IHC marker, podoplanin, was recently introduced as an adjunctive marker for thyroid cancer diagnosis and prognosis and is associated with the progression of papillary thyroid carcinoma (PTC). Several researchers have identified molecular markers to increase the diagnostic accuracy of thyroid lesions of undetermined significance. Four promising molecular markers have been proposed and thoroughly investigated: B-type Raf kinase (BRAF) and RAS, rearranged in transformation/PTC (RET/PTC), paired box gene 8 (Pax8)/peroxisome proliferator-activated receptor gamma (PPARγ). BRAF mutations can be measured by immunohistochemistry using an antibody specific to the mutated protein. In this review, we focused on the limitations of current diagnostic tools and on determining the application of the above-mentioned markers to thyroid nodule diagnosis.

Abstract

In the last decade, conventional diagnosis of thyroid nodules largely depended on fine-needle aspiration (FNA) and ultrasound. However, FNA has a limited ability to distinguish between benign and malignant lesions, especially in cases with indeterminate cytology. Although the clinical course of differentiated thyroid carcinoma is believed to be favorable, delayed diagnosis can make its clinical management difficult. Many immunohistochemical (IHC) or molecular adjunctive markers have been tested to improve the diagnostic accuracy for thyroid nodules. The common IHC markers galectin-3, Hector Battifora mesothelial-1, and cytokeratin-19 are used alone or as part of panels for both FNA and analysis of surgical specimens. A novel IHC marker, podoplanin, was recently introduced as an adjunctive marker for thyroid cancer diagnosis and prognosis and is associated with the progression of papillary thyroid carcinoma (PTC). Several researchers have identified molecular markers to increase the diagnostic accuracy of thyroid lesions of undetermined significance. Four promising molecular markers have been proposed and thoroughly investigated: B-type Raf kinase (BRAF) and RAS, rearranged in transformation/PTC (RET/PTC), paired box gene 8 (Pax8)/peroxisome proliferator-activated receptor gamma (PPARγ). BRAF mutations can be measured by immunohistochemistry using an antibody specific to the mutated protein. In this review, we focused on the limitations of current diagnostic tools and on determining the application of the above-mentioned markers to thyroid nodule diagnosis.

참고문헌 (73)

  1. Fallahi P, "Molecular diagnostics of fine needle aspiration for the presurgical screening of thyroid nodules", Curr Genomics, 15(3), pp.171~177 (2014)
  2. Cheung CC, "Immunohistochemical diagnosis of papillary thyroid carcinoma", Mod Pathol, 14(4), pp.338~342 (2001)
  3. Fischer S, "Application of immunohistochemistry to thyroid neoplasms", Arch Pathol Lab Med, 132(3), pp.359~372 (2008)
  4. Griffith OL, "Biomarker panel diagnosis of thyroid cancer: a critical review", Expert Rev Anticancer Ther, 8(9), pp.1399~1413 (2008)
  5. Singer PA, "Treatment guidelines for patients with thyroid nodules and well-differentiated thyroid cancer. American Thyroid Association", Arch Intern Med, 156(19), pp.2165~2172 (1996)
  6. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, "Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer", Thyroid, 19(11), pp.1167~1214 (2009)
  7. Gasbarri A, "From the bench to the bedside. Galectin-3immunodetection for improving the preoperative diagnosis of the follicular thyroid nodules", Biomed Pharmacother, 58(6-7), pp.356~359 (2004)
  8. Rodrigues HG, "Use of molecular markers in samples obtained from preoperative aspiration of thyroid", Endocr J, 59(5), pp.417~424 (2012)
  9. 박영주, "Diagnostic Value of Galectin-3, HBME-1, Cytokeratin 19, HighMolecular Weight Cytokeratin, Cyclin D1 and p27kip1 in the DifferentialDiagnosis of Thyroid Nodules", Journal of Korean Medical Science, 22(4), pp.621~628 (2007), 대한의학회
  10. Vriens MR, "Diagnostic markers and prognostic factors in thyroid cancer", Future Oncol, 5(8), pp.1283~1293 (2009)
  11. de Matos LL, "Expression of CK-19, galectin-3 and HBME-1 in the differentiation of thyroid lesions: systematic review and diagnostic meta-analysis", Diagn Pathol, 7, pp.97~ (2012)
  12. Yasuoka H, "VEGF-D expression and lymph vessels play an important role for lymph node metastasis in papillary thyroid carcinoma", Mod Pathol, 18(8), pp.1127~1133 (2005)
  13. Scarpino S, "Papillary carcinoma of the thyroid: low expression of NCAM (CD56) is associated with downregulation of VEGF-D production by tumour cells", J Pathol, 212(4), pp.411~419 (2007)
  14. Rudzinska M, "The role of podoplanin in the biology of differentiated thyroid cancers", PLoS One, 9(5), pp.e96541~ (2014)
  15. Shindo K, "Podoplanin expression in the cyst wall correlates with the progression of intraductal papillary mucinous neoplasm", Virchows Arch, 465(3), pp.265~273 (2014)
  16. Hapke MR, "The optically clear nucleus. A reliable sign of papillary carcinoma of the thyroid?", Am J Surg Pathol, 3(1), pp.31~38 (1979)
  17. Miettinen M, "Differential reactivity of HBME-1 and CD15 antibodies in benign and malignant thyroid tumours. Preferential reactivity with malignant tumours", Virchows Arch, 429(4-5), pp.213~219 (1996)
  18. Chiu CG, "Diagnostic utility of galectin-3 in thyroid cancer", Am J Pathol, 176(5), pp.2067~2081 (2010)
  19. Herrmann ME, "Immunohistochemical expression of galectin-3 in benign and malignant thyroid lesions", Arch Pathol Lab Med, 126(6), pp.710~713 (2002)
  20. Kovacs RB, "The investigation of galectin-3 in diseases of the thyroid gland", Eur J Endocrinol, 149(5), pp.449~453 (2003)
  21. Cvejic DS, "Galectin-3 expression in papillary thyroid carcinoma:relation to histomorphologic growth pattern, lymph node metastasis, extrathyroid invasion, and tumor size", Head Neck, 27(12), pp.1049~1055 (2005)
  22. Bartolazzi A, "Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions", Lancet, 357(9269), pp.1644~1650 (2001)
  23. Fernandez PL, "Galectin-3 and laminin expression in neoplastic and non-neoplastic thyroid tissue", J Pathol, 181(1), pp.80~86 (1997)
  24. Maruta J, "Immunostaining of galectin-3 and CD44v6 using fine-needle aspiration for distinguishing follicular carcinoma from adenoma", Diagn Cytopathol, 31(6), pp.392~396 (2004)
  25. Sethi K, "Biomarkers for the diagnosis of thyroid cancer", J Exp Ther Oncol, 8(4), pp.341~352 (2010)
  26. Wallander M, "Follicular variant of papillary carcinoma:reproducibility of histologic diagnosis and utility of HBME-1immunohistochemistry and BRAF mutational analysis as diagnostic adjuncts", Appl Immunohistochem Mol Morphol, 18(3), pp.231~235 (2010)
  27. Erickson LA, "Practical markers used in the diagnosis of endocrine tumors", Adv Anat Pathol, 11(4), pp.175~189 (2004)
  28. Rezk S, "Role of immunohistochemistry in the diagnosis and progression of follicular epithelium-derived thyroid carcinoma", Appl Immunohistochem Mol Morphol, 13(3), pp.256~264 (2005)
  29. Saggiorato E, "Characterization of thyroid 'follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application", Endocr Relat Cancer, 12(2), pp.305~317 (2005)
  30. 최윤라, "Immunoexpression of HBME-1,High Molecular Weight Cytokeratin, Cytokeratin 19,Thyroid Transcription Factor-1,and E-cadherin in Thyroid Carcinomas", Journal of Korean Medical Science, 20(5), pp.853~859 (2005), 대한의학회
  31. Mase T, "HBME-1 immunostaining in thyroid tumors especially in follicular neoplasm", Endocr J, 50(2), pp.173~177 (2003)
  32. Papotti M, "Galectin-3 and HBME-1 expression in well-differentiated thyroid tumors with follicular architecture of uncertain malignant potential", Mod Pathol, 18(4), pp.541~546 (2005)
  33. Prasad ML, "Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors", Mod Pathol, 18(1), pp.48~57 (2005)
  34. Rossi ED, "Immunocytochemical evaluation of thyroid neoplasms on thin-layer smears from fine-needle aspiration biopsies", Cancer, 105(2), pp.87~95 (2005)
  35. Cerilli LA, "Interpretation of RET immunostaining in follicular lesions of the thyroid", Am J Clin Pathol, 118(2), pp.186~193 (2002)
  36. Baloch ZW, "Differential expression of cytokeratins in follicular variant of papillary carcinoma: an immunohistochemical study and its diagnostic utility", Hum Pathol, 30(10), pp.1166~1171 (1999)
  37. Sahoo S, "Cytokeratin 19immunoreactivity in the diagnosis of papillary thyroid carcinoma:a note of caution", Am J Clin Pathol, 116(5), pp.696~702 (2001)
  38. Asa SL, "My approach to oncocytic tumours of the thyroid", J Clin Pathol, 57(3), pp.225~232 (2004)
  39. Rorive S, "Changes in galectin-7 and cytokeratin-19expression during the progression of malignancy in thyroid tumors:diagnostic and biological implications", Mod Pathol, 15(12), pp.1294~1301 (2002)
  40. Nasser SM, "Fine-needle aspiration biopsy of papillary thyroid carcinoma: diagnostic utility of cytokeratin 19 immunostaining", Cancer, 90(5), pp.307~311 (2000)
  41. Koperek O, "Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma", Am J Surg Pathol, 36(6), pp.844~850 (2012)
  42. Kim HS, "Factors influencing the detection of the BRAF T1799A mutation in papillary thyroid carcinoma", Oncol Rep, 25(6), pp.1639~1644 (2011)
  43. Kim SK, "Pyrosequencing analysis for detection of a BRAFV600E mutation in an FNAB specimen of thyroid nodules", Diagn Mol Pathol, 17(2), pp.118~125 (2008)
  44. Lima J, "BRAF mutations are not a major event in post-Chernobyl childhood thyroid carcinomas", J Clin Endocrinol Metab, 89(9), pp.4267~4271 (2004)
  45. Wicki A, "The potential role of podoplanin in tumour invasion", Br J Cancer, 96(1), pp.1~5 (2007)
  46. Kim MI, "Diagnostic use of molecular markers in the evaluation of thyroid nodules", Endocr Pract, 18(5), pp.796~802 (2012)
  47. Nikiforov YE, "Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples", J Clin Endocrinol Metab, 96(11), pp.3390~3397 (2011)
  48. Bartolazzi A, "Galectin-3-expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fineneedle aspiration cytology: a prospective multicentre study", Lancet Oncol, 9(6), pp.543~549 (2008)
  49. Alexander EK, "Preoperative diagnosis of benign thyroid nodules with indeterminate cytology", N Engl J Med, 367(8), pp.705~715 (2012)
  50. Garnett MJ, "Guilty as charged: B-RAF is a human oncogene", Cancer Cell, 6(4), pp.313~319 (2004)
  51. Xing M, "Genetic alterations in the phosphatidylinositol-3kinase", Akt pathway in thyroid cancer, 2010, pp.20(7), 697~706
  52. Kebebew E, "The prevalence and prognostic value of BRAF mutation in thyroid cancer", Ann Surg, 246(3), pp.466~471 (2007)
  53. Cohen Y, "Mutational analysis of BRAF in fine needle aspiration biopsies of the thyroid: a potential application for the preoperative assessment of thyroid nodules", Clin Cancer Res, 10(8), pp.2761~2765 (2004)
  54. Nikiforova MN, "Molecular diagnostics and predictors in thyroid cancer", Thyroid, 19(12), pp.1351~1361 (2009)
  55. Kouniavsky G, "The quest for diagnostic molecular markers for thyroid nodules with indeterminate or suspicious cytology", J Surg Oncol, 105(5), pp.438~443 (2012)
  56. Chung KW, "Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis, especially in BRAF600E mutation-prevalent area", Clin Endocrinol (Oxf), 65(5), pp.660~666 (2006)
  57. Kim SK, "Surgical results of thyroid nodules according to a management guideline based on the BRAF(V600E) mutation status", J Clin Endocrinol Metab, 96(3), pp.658~664 (2011)
  58. Xing M, "BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer", J Clin Endocrinol Metab, 90(12), pp.6373~6379 (2005)
  59. Xing M, "BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications", Endocr Rev, 28(7), pp.742~762 (2007)
  60. Xing M, "Prognostic utility of BRAF mutation in papillary thyroid cancer", Mol Cell Endocrinol, 321(1), pp.86~93 (2010)
  61. Xing M, "Progress in molecular-based management of differentiated thyroid cancer", Lancet, 381(9871), pp.1058~1069 (2013)
  62. Xing M, "Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer", JAMA, 309(14), pp.1493~1501 (2013)
  63. Ciampi R, "RET", PTC rearrangements and BRAF mutations in thyroid tumorigenesis, 2007, pp.148(3), 936~941
  64. Cheung CC, "Analysis of ret", PTC gene rearrangements refines the fine needle aspiration diagnosis of thyroid cancer, 2001, pp.86(5), 2187~2190
  65. Pizzolanti G, "Fine-needle aspiration molecular analysis for the diagnosis of papillary thyroid carcinoma through BRAF V600E mutation and RET", PTC rearrangement, 2007, pp.17(11), 1109~1115
  66. Ishizaka Y, "Detection of retTPC", PTC transcripts in thyroid adenomas and adenomatous goiter by an RT-PCR method, 1991, pp.6(9), 1667~1672
  67. Repasky GA, "Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis?", Trends Cell Biol, 14(11), pp.639~647 (2004)
  68. Basolo F, "N-ras mutation in poorly differentiated thyroid carcinomas: correlation with bone metastases and inverse correlation to thyroglobulin expression", Thyroid, 10(1), pp.19~23 (2000)
  69. Marques AR, "Expression of PAX8-PPAR gamma 1rearrangements in both follicular thyroid carcinomas and adenomas", J Clin Endocrinol Metab, 87(8), pp.3947~3952 (2002)
  70. Sahin M, "PPARgamma staining as a surrogate for PAX8", PPAR gamma fusion oncogene expression in follicular neoplasms:clinicopathological correlation and histopathological diagnostic value, 2005, pp.90(1), 463~468
  71. Weber KB, "The use of a combination of galectin-3 and thyroid peroxidase for the diagnosis and prognosis of thyroid cancer", Am J Clin Pathol, 122(4), pp.524~531 (2004)
  72. Oestreicher-Kedem Y, "Diagnostic value of galectin-3as a marker for malignancy in follicular patterned thyroid lesions", Head Neck, 26(11), pp.960~966 (2004)
  73. Nikiforova MN, "RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma", J Clin Endocrinol Metab, 88(5), pp.2318~2326 (2003)

이 간행물의 다른 논문 (17건)

갑상선암과 방사선김종순pp. 1-7갑상선분화암의 수술 후 감시: 영상의학과의사의 관점곽진영pp. 8-13저용량 대 고용량 방사성요오드 치료원경숙pp. 14-18경액와 액와부 접근법 로봇 갑상선 수술 후 삶의 질 변화이잔디, 정웅윤pp. 19-25방사성요오드 치료저항성 갑상선암에서 방사성요오드 병용치료의 새로운 전략팽진철, 정준기, 오소원pp. 26-35
원문 보기